Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 65 entries
Sorted by: Best Match Show Resources per page
Assessment of vocation of rifabutin and rifapentine in replace of rifampcin in drug resistance leprosy patients: a molecular simulation study.

Molecular biology research communications

Mohanty PS, Naaz F, Bansal AK, Gupta UD.
PMID: 29071280
Mol Biol Res Commun. 2017 Sep;6(3):113-122. doi: 10.22099/mbrc.2017.4084.

The emergence of drug resistance in leprosy is a major hurdle in leprosy elimination programme. Although the problem of drug resistance is presently not acute, it is important that we collect data more systematically and monitor the trend carefully...

Cite
Mohanty PS, Naaz F, Bansal AK, et al. Assessment of vocation of rifabutin and rifapentine in replace of rifampcin in drug resistance leprosy patients: a molecular simulation study. Mol Biol Res Commun. 2017;6(3):113-122doi: 10.22099/mbrc.2017.4084.
Mohanty, P. S., Naaz, F., Bansal, A. K., & Gupta, U. D. (2017). Assessment of vocation of rifabutin and rifapentine in replace of rifampcin in drug resistance leprosy patients: a molecular simulation study. Molecular biology research communications, 6(3), 113-122. https://doi.org/10.22099/mbrc.2017.4084
Mohanty, Partha Sarathi, et al. "Assessment of vocation of rifabutin and rifapentine in replace of rifampcin in drug resistance leprosy patients: a molecular simulation study." Molecular biology research communications vol. 6,3 (2017): 113-122. doi: https://doi.org/10.22099/mbrc.2017.4084
Mohanty PS, Naaz F, Bansal AK, Gupta UD. Assessment of vocation of rifabutin and rifapentine in replace of rifampcin in drug resistance leprosy patients: a molecular simulation study. Mol Biol Res Commun. 2017 Sep;6(3):113-122. doi: 10.22099/mbrc.2017.4084. PMID: 29071280; PMCID: PMC5640893.
Copy Download .nbib Format: NLM
Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals.

International journal of antimicrobial agents

Chan SL, Yew WW, Porter JH, McAdam KP, Allen BW, Dickinson JM, Ellard GA, Mitchison DA.
PMID: 18611569
Int J Antimicrob Agents. 1994;3(4):267-74. doi: 10.1016/0924-8579(94)90054-x.

Bioavailability was measured by rifapentine (RPE) serum concentrations and by the urinary ratio between RPE and creatinine, in specimens obtained 4-50 h after 600 mg RPE preceded by food. The bioavailabilities of RPEs manufactured in China and by a...

Cite
Chan SL, Yew WW, Porter JH, et al. Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals. Int J Antimicrob Agents. 1994;3(4):267-74doi: 10.1016/0924-8579(94)90054-x.
Chan, S. L., Yew, W. W., Porter, J. H., McAdam, K. P., Allen, B. W., Dickinson, J. M., Ellard, G. A., & Mitchison, D. A. (1994). Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals. International journal of antimicrobial agents, 3(4), 267-74. https://doi.org/10.1016/0924-8579(94)90054-x
Chan, S L, et al. "Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals." International journal of antimicrobial agents vol. 3,4 (1994): 267-74. doi: https://doi.org/10.1016/0924-8579(94)90054-x
Chan SL, Yew WW, Porter JH, McAdam KP, Allen BW, Dickinson JM, Ellard GA, Mitchison DA. Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals. Int J Antimicrob Agents. 1994;3(4):267-74. doi: 10.1016/0924-8579(94)90054-x. PMID: 18611569.
Copy Download .nbib Format: NLM
Prospects for Tuberculosis Elimination in the United States: Results of a Transmission Dynamic Model.

American journal of epidemiology

Menzies NA, Cohen T, Hill AN, Yaesoubi R, Galer K, Wolf E, Marks SM, Salomon JA.
PMID: 29762657
Am J Epidemiol. 2018 Sep 01;187(9):2011-2020. doi: 10.1093/aje/kwy094.

We estimated long-term tuberculosis (TB) trends in the US population and assessed prospects for TB elimination. We used a detailed simulation model allowing for changes in TB transmission, immigration, and other TB risk determinants. Five hypothetical scenarios were evaluated...

Cite
Menzies NA, Cohen T, Hill AN, et al. Prospects for Tuberculosis Elimination in the United States: Results of a Transmission Dynamic Model. Am J Epidemiol. 2018;187(9):2011-2020doi: 10.1093/aje/kwy094.
Menzies, N. A., Cohen, T., Hill, A. N., Yaesoubi, R., Galer, K., Wolf, E., Marks, S. M., & Salomon, J. A. (2018). Prospects for Tuberculosis Elimination in the United States: Results of a Transmission Dynamic Model. American journal of epidemiology, 187(9), 2011-2020. https://doi.org/10.1093/aje/kwy094
Menzies, Nicolas A, et al. "Prospects for Tuberculosis Elimination in the United States: Results of a Transmission Dynamic Model." American journal of epidemiology vol. 187,9 (2018): 2011-2020. doi: https://doi.org/10.1093/aje/kwy094
Menzies NA, Cohen T, Hill AN, Yaesoubi R, Galer K, Wolf E, Marks SM, Salomon JA. Prospects for Tuberculosis Elimination in the United States: Results of a Transmission Dynamic Model. Am J Epidemiol. 2018 Sep 01;187(9):2011-2020. doi: 10.1093/aje/kwy094. PMID: 29762657; PMCID: PMC6119121.
Copy Download .nbib Format: NLM
Potential inhibitors of SARS-cov-2 RNA dependent RNA polymerase protein: molecular docking, molecular dynamics simulations and MM-PBSA analyses.

Journal of biomolecular structure & dynamics

Elkarhat Z, Charoute H, Elkhattabi L, Barakat A, Rouba H.
PMID: 32873176
J Biomol Struct Dyn. 2022 Jan;40(1):361-374. doi: 10.1080/07391102.2020.1813628. Epub 2020 Sep 02.

The SARS-cov-2 RNA dependent RNA polymerase (nsp12) is a crucial viral enzyme that catalyzes the replication of RNA from RNA templates. The fixation of some ligands in the active site may alter the viral life cycle. The aim of...

Cite
Elkarhat Z, Charoute H, Elkhattabi L, et al. Potential inhibitors of SARS-cov-2 RNA dependent RNA polymerase protein: molecular docking, molecular dynamics simulations and MM-PBSA analyses. J Biomol Struct Dyn. 2020;40(1):361-374doi: 10.1080/07391102.2020.1813628.
Elkarhat, Z., Charoute, H., Elkhattabi, L., Barakat, A., & Rouba, H. (2022). Potential inhibitors of SARS-cov-2 RNA dependent RNA polymerase protein: molecular docking, molecular dynamics simulations and MM-PBSA analyses. Journal of biomolecular structure & dynamics, 40(1), 361-374. https://doi.org/10.1080/07391102.2020.1813628
Elkarhat, Zouhair, et al. "Potential inhibitors of SARS-cov-2 RNA dependent RNA polymerase protein: molecular docking, molecular dynamics simulations and MM-PBSA analyses." Journal of biomolecular structure & dynamics vol. 40,1 (2022): 361-374. doi: https://doi.org/10.1080/07391102.2020.1813628
Elkarhat Z, Charoute H, Elkhattabi L, Barakat A, Rouba H. Potential inhibitors of SARS-cov-2 RNA dependent RNA polymerase protein: molecular docking, molecular dynamics simulations and MM-PBSA analyses. J Biomol Struct Dyn. 2022 Jan;40(1):361-374. doi: 10.1080/07391102.2020.1813628. Epub 2020 Sep 02. PMID: 32873176.
Copy Download .nbib Format: NLM
Isolated hepatic tuberculosis associated with portal vein thrombosis and hepatitis B virus coinfection: A case report and review of the literature.

World journal of clinical cases

Zheng SM, Lin N, Tang SH, Yang JY, Wang HQ, Luo SL, Zhang Y, Mu D.
PMID: 34786418
World J Clin Cases. 2021 Oct 26;9(30):9310-9319. doi: 10.12998/wjcc.v9.i30.9310.

BACKGROUND: While tuberculosis (TB) itself is a common disease, isolated TB of the liver is a rare entity. Tubercular involvement of the liver is more commonly a part of a disseminated disease of the hepatic parenchyma. In contrast, isolated...

Cite
Zheng SM, Lin N, Tang SH, et al. Isolated hepatic tuberculosis associated with portal vein thrombosis and hepatitis B virus coinfection: A case report and review of the literature. World J Clin Cases. 2021;9(30):9310-9319doi: 10.12998/wjcc.v9.i30.9310.
Zheng, S. M., Lin, N., Tang, S. H., Yang, J. Y., Wang, H. Q., Luo, S. L., Zhang, Y., & Mu, D. (2021). Isolated hepatic tuberculosis associated with portal vein thrombosis and hepatitis B virus coinfection: A case report and review of the literature. World journal of clinical cases, 9(30), 9310-9319. https://doi.org/10.12998/wjcc.v9.i30.9310
Zheng, Shu-Mei, et al. "Isolated hepatic tuberculosis associated with portal vein thrombosis and hepatitis B virus coinfection: A case report and review of the literature." World journal of clinical cases vol. 9,30 (2021): 9310-9319. doi: https://doi.org/10.12998/wjcc.v9.i30.9310
Zheng SM, Lin N, Tang SH, Yang JY, Wang HQ, Luo SL, Zhang Y, Mu D. Isolated hepatic tuberculosis associated with portal vein thrombosis and hepatitis B virus coinfection: A case report and review of the literature. World J Clin Cases. 2021 Oct 26;9(30):9310-9319. doi: 10.12998/wjcc.v9.i30.9310. PMID: 34786418; PMCID: PMC8567534.
Copy Download .nbib Format: NLM
Targeting Non-Replicating .

International journal of molecular sciences

Egorova A, Salina EG, Makarov V.
PMID: 34948114
Int J Mol Sci. 2021 Dec 10;22(24). doi: 10.3390/ijms222413317.

Latent tuberculosis infection (LTBI) represents a major challenge to curing TB disease. Current guidelines for LTBI management include only three older drugs and their combinations-isoniazid and rifamycins (rifampicin and rifapentine). These available control strategies have little impact on latent...

Cite
Egorova A, Salina EG, Makarov V. Targeting Non-Replicating . Int J Mol Sci. 2021;22(24)doi: 10.3390/ijms222413317.
Egorova, A., Salina, E. G., & Makarov, V. (2021). Targeting Non-Replicating . International journal of molecular sciences, 22(24), . https://doi.org/10.3390/ijms222413317
Egorova, Anna, et al. "Targeting Non-Replicating ." International journal of molecular sciences vol. 22,24 (2021). doi: https://doi.org/10.3390/ijms222413317
Egorova A, Salina EG, Makarov V. Targeting Non-Replicating . Int J Mol Sci. 2021 Dec 10;22(24). doi: 10.3390/ijms222413317. PMID: 34948114.
Copy Download .nbib Format: NLM
In vitro Synergism of Six Antituberculosis Agents Against Drug-Resistant .

Infection and drug resistance

Ying R, Huang X, Gao Y, Wang J, Liu Y, Sha W, Yang H.
PMID: 34548797
Infect Drug Resist. 2021 Sep 14;14:3729-3736. doi: 10.2147/IDR.S322563. eCollection 2021.

BACKGROUND: Retreatment tuberculosis (TB) has become a major source of drug-resistant TB. In contrast to the combination of isoniazid (INH) and rifampicin (RIF), that of pasiniazid (Pa) and rifabutin (RFB) or rifapentine (RFP) appears to have better activity in...

Cite
Ying R, Huang X, Gao Y, et al. In vitro Synergism of Six Antituberculosis Agents Against Drug-Resistant . Infect Drug Resist. 2021;14:3729-3736doi: 10.2147/IDR.S322563.
Ying, R., Huang, X., Gao, Y., Wang, J., Liu, Y., Sha, W., & Yang, H. (2021). In vitro Synergism of Six Antituberculosis Agents Against Drug-Resistant . Infection and drug resistance, 143729-3736. https://doi.org/10.2147/IDR.S322563
Ying, Ruoyan, et al. "In vitro Synergism of Six Antituberculosis Agents Against Drug-Resistant ." Infection and drug resistance vol. 14 (2021): 3729-3736. doi: https://doi.org/10.2147/IDR.S322563
Ying R, Huang X, Gao Y, Wang J, Liu Y, Sha W, Yang H. In vitro Synergism of Six Antituberculosis Agents Against Drug-Resistant . Infect Drug Resist. 2021 Sep 14;14:3729-3736. doi: 10.2147/IDR.S322563. eCollection 2021. PMID: 34548797; PMCID: PMC8449861.
Copy Download .nbib Format: NLM
Retraction: Isoniazid and Rifapentine Treatment Eradicates Persistent .

American journal of respiratory and critical care medicine

[No authors listed]
PMID: 33856282
Am J Respir Crit Care Med. 2021 Apr 15;203(8):1045. doi: 10.1164/rccm.v203retraction1.

No abstract available.

Cite
Retraction: Isoniazid and Rifapentine Treatment Eradicates Persistent . Am J Respir Crit Care Med. 2021;203(8):1045doi: 10.1164/rccm.v203retraction1.
(2021). Retraction: Isoniazid and Rifapentine Treatment Eradicates Persistent . American journal of respiratory and critical care medicine, 203(8), 1045. https://doi.org/10.1164/rccm.v203retraction1
"Retraction: Isoniazid and Rifapentine Treatment Eradicates Persistent ." American journal of respiratory and critical care medicine vol. 203,8 (2021): 1045. doi: https://doi.org/10.1164/rccm.v203retraction1
Retraction: Isoniazid and Rifapentine Treatment Eradicates Persistent . Am J Respir Crit Care Med. 2021 Apr 15;203(8):1045. doi: 10.1164/rccm.v203retraction1. PMID: 33856282; PMCID: PMC8048750.
Copy Download .nbib Format: NLM
Does Isoniazid Preventive Therapy Provide Better Treatment Outcomes in HIV-Infected Individuals in Northern Ethiopia? A Retrospective Cohort Study.

AIDS research and treatment

Atey TM, Bitew H, Asgedom SW, Endrias A, Berhe DF.
PMID: 32411454
AIDS Res Treat. 2020 Jan 21;2020:7025738. doi: 10.1155/2020/7025738. eCollection 2020.

OBJECTIVES: Early antiretroviral therapy (ART), isoniazid preventive therapy (IPT), and isoniazid-rifapentine (3HP) are effective strategies for preventing tuberculosis (TB) among people living with HIV (PLHIV). The study aimed to determine the effect of IPT on the TB incidence, follow-up...

Cite
Atey TM, Bitew H, Asgedom SW, et al. Does Isoniazid Preventive Therapy Provide Better Treatment Outcomes in HIV-Infected Individuals in Northern Ethiopia? A Retrospective Cohort Study. AIDS Res Treat. 2020;2020:7025738doi: 10.1155/2020/7025738.
Atey, T. M., Bitew, H., Asgedom, S. W., Endrias, A., & Berhe, D. F. (2020). Does Isoniazid Preventive Therapy Provide Better Treatment Outcomes in HIV-Infected Individuals in Northern Ethiopia? A Retrospective Cohort Study. AIDS research and treatment, 20207025738. https://doi.org/10.1155/2020/7025738
Atey, Tesfay Mehari, et al. "Does Isoniazid Preventive Therapy Provide Better Treatment Outcomes in HIV-Infected Individuals in Northern Ethiopia? A Retrospective Cohort Study." AIDS research and treatment vol. 2020 (2020): 7025738. doi: https://doi.org/10.1155/2020/7025738
Atey TM, Bitew H, Asgedom SW, Endrias A, Berhe DF. Does Isoniazid Preventive Therapy Provide Better Treatment Outcomes in HIV-Infected Individuals in Northern Ethiopia? A Retrospective Cohort Study. AIDS Res Treat. 2020 Jan 21;2020:7025738. doi: 10.1155/2020/7025738. eCollection 2020. PMID: 32411454; PMCID: PMC7204289.
Copy Download .nbib Format: NLM
Potential inhibitors of SARS-cov-2 RNA dependent RNA polymerase protein: molecular docking, molecular dynamics simulations and MM-PBSA analyses.

Journal of biomolecular structure & dynamics

Elkarhat Z, Charoute H, Elkhattabi L, Barakat A, Rouba H.
PMID: 32873176
J Biomol Struct Dyn. 2020 Sep 02;1-14. doi: 10.1080/07391102.2020.1813628. Epub 2020 Sep 02.

The SARS-cov-2 RNA dependent RNA polymerase (nsp12) is a crucial viral enzyme that catalyzes the replication of RNA from RNA templates. The fixation of some ligands in the active site may alter the viral life cycle. The aim of...

Cite
Elkarhat Z, Charoute H, Elkhattabi L, et al. Potential inhibitors of SARS-cov-2 RNA dependent RNA polymerase protein: molecular docking, molecular dynamics simulations and MM-PBSA analyses. J Biomol Struct Dyn. 2020;1-14doi: 10.1080/07391102.2020.1813628.
Elkarhat, Z., Charoute, H., Elkhattabi, L., Barakat, A., & Rouba, H. (2020). Potential inhibitors of SARS-cov-2 RNA dependent RNA polymerase protein: molecular docking, molecular dynamics simulations and MM-PBSA analyses. Journal of biomolecular structure & dynamics, 1-14. https://doi.org/10.1080/07391102.2020.1813628
Elkarhat, Zouhair, et al. "Potential inhibitors of SARS-cov-2 RNA dependent RNA polymerase protein: molecular docking, molecular dynamics simulations and MM-PBSA analyses." Journal of biomolecular structure & dynamics vol. (2020): 1-14. doi: https://doi.org/10.1080/07391102.2020.1813628
Elkarhat Z, Charoute H, Elkhattabi L, Barakat A, Rouba H. Potential inhibitors of SARS-cov-2 RNA dependent RNA polymerase protein: molecular docking, molecular dynamics simulations and MM-PBSA analyses. J Biomol Struct Dyn. 2020 Sep 02;1-14. doi: 10.1080/07391102.2020.1813628. Epub 2020 Sep 02. PMID: 32873176.
Copy Download .nbib Format: NLM
Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.

Evidence-based child health : a Cochrane review journal

Sharma SK, Sharma A, Kadhiravan T, Tharyan P.
PMID: 25404581
Evid Based Child Health. 2014 Mar;9(1):169-294. doi: 10.1002/ebch.1962.

BACKGROUND: Preventing active tuberculosis (TB) from developing in people with latent tuberculosis infection (LTBI) is important for global TB control. Isoniazid (INH) for six to nine months has 60% to 90% protective efficacy, but the treatment period is long,...

Cite
Sharma SK, Sharma A, Kadhiravan T, et al. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Evid Based Child Health. 2014;9(1):169-294doi: 10.1002/ebch.1962.
Sharma, S. K., Sharma, A., Kadhiravan, T., & Tharyan, P. (2014). Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Evidence-based child health : a Cochrane review journal, 9(1), 169-294. https://doi.org/10.1002/ebch.1962
Sharma, Surendra K, et al. "Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB." Evidence-based child health : a Cochrane review journal vol. 9,1 (2014): 169-294. doi: https://doi.org/10.1002/ebch.1962
Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Evid Based Child Health. 2014 Mar;9(1):169-294. doi: 10.1002/ebch.1962. PMID: 25404581.
Copy Download .nbib Format: NLM
Recent Developments in Epidemiology, Treatment, and Diagnosis of Tuberculosis.

Current infectious disease reports

Hamilton CD.
PMID: 11095771
Curr Infect Dis Rep. 1999 Apr;1(1):80-88. doi: 10.1007/s11908-999-0014-6.

The resurgence in cases of active tuberculosis in North America in the past decade has prompted increases in funding for tuberculosis treatment, research, and education. As a result, the number of new cases of tuberculosis has declined and cases...

Cite
Hamilton CD. Recent Developments in Epidemiology, Treatment, and Diagnosis of Tuberculosis. Curr Infect Dis Rep. 1999;1(1):80-88doi: 10.1007/s11908-999-0014-6.
Hamilton, C. D. (1999). Recent Developments in Epidemiology, Treatment, and Diagnosis of Tuberculosis. Current infectious disease reports, 1(1), 80-88. https://doi.org/10.1007/s11908-999-0014-6
Hamilton. "Recent Developments in Epidemiology, Treatment, and Diagnosis of Tuberculosis." Current infectious disease reports vol. 1,1 (1999): 80-88. doi: https://doi.org/10.1007/s11908-999-0014-6
Hamilton CD. Recent Developments in Epidemiology, Treatment, and Diagnosis of Tuberculosis. Curr Infect Dis Rep. 1999 Apr;1(1):80-88. doi: 10.1007/s11908-999-0014-6. PMID: 11095771.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 65 entries